Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Owl Therapeutics to Present Latest Data at the RESI JPM San Francisco 2024 Conference
Liquidia Corporation Announces $100 Million in New Financings
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
Sagard Healthcare Announces Closing of Credit Facility and Recent Investment Highlights
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
 1   2   3   4   5     6    7   8   9   10   11 
 <<   <   >   >>